POZEN Presents Phase 1 Data at Digestive Disease Week 2012

SAN DIEGO–(CRWENewswire)–POZEN Inc. (NASDAQ:POZN), a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from a Phase 1 study that found that the investigational compound, PA32540, provides faster protection compared with delayed-release, enteric-coated omeprazole (40 mg), as measured by mean time to gastric pH. These data were presented for the first time at Digestive Disease Week (DDW) 2012 in San Diego, California at the San Diego Convention Center on May 19, 2012, at 9:15 a.m. (PT).

“In this study, the mean time to a gastric pH of greater than 4.0 was faster with PA32540 than with 40 mg of delayed-release, enteric-coated omeprazole,” said Philip B. Miner, Jr., M.D., President and Medical Director of the Oklahoma Foundation for Digestive Research and co-author of the study. “In addition, the 24-hour pH control achieved with the immediate release form of omeprazole in PA32540 should be sufficient for control of gastric acidity in patients taking chronic aspirin therapy for secondary cardiovascular prevention.”

About Study 112

Study 112 is a Phase 1, single-center, open-label, randomized, two-way crossover study that examined 26 healthy male and female volunteers who were H. pylori negative. The study rationale was to gain an understanding of the anti-secretory and gastrointestinal (GI) therapeutic effect of the immediate-release omeprazole in PA32540. Subjects received either PA32540 once daily for seven days or enteric-coated aspirin (325 mg) plus enteric-coated omeprazole (40 mg) administered concomitantly once daily for seven days. After at least a seven-day washout, subjects were crossed over to the alternate treatment. Gastric pH and pharmacokinetics were measured over 24 hours on day seven of each treatment period.

Key Findings

* Mean time to first gastric pH >4 was significantly faster with PA32540 compared to the enteric-coated aspirin + enteric-coated omeprazole group (PA32540: 17 minutes; enteric-coated aspirin + enteric-coated omeprazole: 36 minutes; p=0.011).

* The percent time gastric pH >4 was 50.6 percent for PA32540 and 57.6 percent for enteric-coated aspirin + enteric-coated omeprazole group (p=0.004).

* The relative bioavailability of omeprazole following seven daily doses with PA32540 was 43 percent lower than that from enteric-coated omeprazole 40 mg.

“In patients who require aspirin therapy and are at risk for UGI events, PA32540 could provide a consistent and coordinated therapeutic approach to cardio protection and reduced risk of UGI injury,” said John G. Fort, M.D., Chief Medical Officer of POZEN and co-author of the study. “These Phase 1 study findings support the coordinated-release design of PA32540, with the omeprazole in the outer layer of the tablet released first followed by aspirin. The Phase 3 top-line results of PA32540 support the gastro protective effects of PA32540.”

About PA

POZEN is creating a portfolio of integrated aspirin therapies – the PA platform. The products in the PA portfolio are intended to significantly reduce GI ulcers and other GI complications compared to taking aspirin alone.

The first candidate is PA32540. It is a coordinated-delivery tablet combining immediate-release omeprazole, a proton pump inhibitor, layered around pH-sensitive aspirin. This novel, patented product is administered orally once a day and will be indicated for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers.

About POZEN

POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained U.S. Food and Drug Administration (FDA) approval of two self-invented products in two years. Funded by these milestone/royalty streams, POZEN is now creating a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

POZEN is currently seeking strategic partners to help maximize the opportunity for its portfolio assets.

The Company’s common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on current market data and research (including third party and POZEN sponsored market studies and reports), management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence on AstraZeneca for the sales and marketing of VIMOVO™; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended March 31, 2012. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Contact:

POZEN Inc.
Bill Hodges, 919-913-1030
Chief Financial Officer
or
Stephanie Bonestell, 919-913-1030
Manager, Investor Relations & Public Relations

Source: POZEN Inc.

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at http://www.crwenewswire.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Category: Press Releases

Tags: aspirin, aspirin therapies, cardiovascular disease, Digestive Disease, gastric ph, gastrointestinal, NASDAQ:POZN, omeprazole, PA32540, pharmacokinetics, POZEN, POZN, US Food and Drug Administration

 

 

ALLEGAN, Mich., May 18, 2012 (CRWENewswire) — Perrigo Company (Nasdaq:PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for Lansoprazole capsules (15 mg). Shipments of product to customers have already begun.

This new product for the U.S. store brand market is bioequivalent to Novartis’ Prevacid® 24HR capsules (15 mg) and is indicated for the treatment of frequent heartburn, which occurs two or more days in a week. Sales for Prevacid OTC were approximately $220 million.

Perrigo’s Chairman, President and CEO Joseph C. Papa stated, “This is another example of Perrigo’s continued leadership and commitment to bring key new products to the store brand OTC market. Perrigo continues to be focused on our mission of making quality healthcare more affordable for consumers. We are pleased to be in a position to bring this important new product to market – for our retail and wholesale customers’ store brand product portfolios and to U.S. consumers, who will realize considerable savings now that they can purchase a high quality, value priced alternative to the national brand.”

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world’s largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company’s primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. These and other important factors, including those discussed under “Risk Factors” in the Company’s Form 10-K for the year ended June 25, 2011, as well as the Company’s subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Perrigo Company

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at http://www.crwenewswire.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Category: Press Releases

Tags: active pharmaceutical ingredients, generic prescription, heartburn, infant formulas, Lansoprazole, NASDAQ:PRGO, Novartis, nutritional products, OTC market, OTC pharmaceutical, Perrigo, Perrigo Co, Prevacid, PRGO

 

 

Marsh & McLennan Companies, Inc. (NYSE:MMC) held its annual meeting of shareholders, at which the Company announced that its Board of Directors has voted to increase the Company’s quarterly cash dividend by 5 percent to $.23 per share on outstanding common stock.

The dividend is payable on August 15, 2012 to shareholders of record on July 11, 2012.

*****************

CRWE, Crown Equity Holdings Inc., CRWE.OB

When it comes to reaching a wide range of customers, no other medium can beat Internet. By advertising on the Internet, a company in one part of the world can find customers in the other.

CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.

CRWE’s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.

CRWE’s division CRWE AD-Services (www.crwe-adservices.com), is a full service multimedia advertising company specializing in internet marketing. It provides modern and unique advertising campaigns, dedicated to offering the most cost effective advertising solutions.

Internet advertising has broken all geographical restrictions that existed with other mediums. Global companies, small local businesses, anybody and everybody can increase their product sales and profits by online advertising.

More about CRWE at www.crownequityholdings.com.

*****************

Devon Energy Corporation (NYSE:DVN) reported that its management will present at the UBS Global Oil & Gas Conference in Austin, Texas on Wednesday, May 23, 2012, at 11:20 a.m. Central Time (12:20 p.m. Eastern Time).

The event will be available to the public via internet webcast. A link to the webcast will be accessible from Devon’s home page.

*****************

The Toro Company (NYSE:TTC) will release its fiscal 2012 second quarter results on Thursday, May 24, 2012, at approximately 7:30 a.m. CDT.

The company will also hold its investor earnings call on that day.

***********************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreetNewsAlert.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://crwewallstreetnewsalert.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreetNewsAlert.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Category: Stock Alerts

Tags: Crown Equity Holdings, CRWE, Devon Energy, DVN, Marsh and McLennan, MMC, NYSE:DVN, NYSE:MMC, NYSE:TTC, OTC:CRWE, Toro Company

 

 

GSI Technology, Inc. (Nasdaq:GSIT) is scheduled to speak at the 13th Annual B. Riley & Co. Investor Conference to be held in Santa Monica, Calif., on May 21-23, 2012.

*****************

Crown Equity Holdings Inc. (CRWE.OB) offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.

CRWE’s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.

Social media is becoming a standard channel for instant communication, online marketing and sharing of knowledge.

One increasingly popular part of social media is online video. Not only is video being used for marketing, but it’s also becoming a common method of communicating and sharing.

CRWE Tube (www.crwetube.com), a video sharing site of CRWE, allows billions of people around the world to upload, watch and share original videos.

More about CRWE at www.crownequityholdings.com.

*****************

WebMediaBrands Inc. (Nasdaq:WEBM) reported the launch of its new conference, Social Curation Summit (#socialcurationsummit), to be held on July 31, 2012 at the New Yorker Hotel in New York City.

The event will be the first ever full-day conference to explore the business of social content curation and visual communities.

*****************

Agilent Technologies Inc. (NYSE:A) and EQT, the Sweden-based private equity group, today announced the execution of a definitive agreement for Agilent to acquire Dako, the Denmark-based cancer diagnostic company. The $2.2 billion acquisition (on a debt-free basis) is the largest in Agilent’s history.

***********************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreetNewsAlert.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://crwewallstreetnewsalert.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreetNewsAlert.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Category: Stock Alerts

Tags: Agilent, Crown Equity Holdings, CRWE, GSI Technology, GSIT, Nasdaq:GSIT, NASDAQ:WEBM, NYSE:A, OTC:CRWE, video internet, video sharing, WEBM, WebMediaBrands

 

 

Ultralife Corporation (Nasdaq:ULBI) will showcase a full array of energy storage and communication systems new product platforms at the Special Operations Forces Industry Conference (SOFIC) in Tampa, Florida on May 22nd to May 24th.

*****************

Crown Equity Holdings Inc., (CRWE.OB) offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. CRWE‘s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.

CRWE’s subsidiary Crown Tele Services Inc. (www.crownteleservices.com) is a provider of affordable, world class Voice Over Internet Protocol (VoIP) communications solutions .

Businesses are always looking for ways to cut costs. Due to its low operational costs, VoIP is a great choice for conducting day-to-day business communications. It enables business organizations to route phone calls over data networks that are already there, eliminating the need to maintain separate networks for voice and data. Besides this, due to the innate open source VoIP features that facilitate video conferencing, call forwarding, IVR, caller identification and redial free of cost, it appears a cheaper alternative as opposed to seeking these services from conventional telecoms companies who levy additional charges for these extra services.

More about CRWE at www.crownequityholdings.com.

*****************

ChinaCache International Holdings Ltd. (Nasdaq:CCIH), the leading total solutions provider of internet content and application delivery services in China, reported that it will participate in Cowen and Company’s 40th Annual Technology, Media & Telecom Conference in New York, on May 31, 2012 at 12:30PM – 1:10PM local time.

*****************

Motorcar Parts of America, Inc. (Nasdaq:MPAA) is scheduled to make a presentation on Wednesday, May 23, 2012 at 9:30 a.m. Pacific time at B. Riley & Company’s 13th Annual Investor Conference at the Loews Santa Monica Beach Hotel in Southern California.

***********************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreetNewsAlert.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://crwewallstreetnewsalert.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreetNewsAlert.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Category: Stock Alerts

Tags: ChinaCache, Crown Equity Holdings, CRWE, Motorcar Parts of America, Nasdaq:CCIH, Nasdaq:MPAA, Nasdaq:ULBI, OTC:CRWE, Ultralife